Pa. Judge Explains Call To Keep $2.5M J&J Risperdal Verdict

Law360, Philadelphia (August 14, 2017, 4:09 PM EDT) -- A Pennsylvania state judge has explained his reason for denying a Johnson & Johnson unit’s request for a new trial over abnormal breast growth allegedly linked to the drug Risperdal, saying the company's “extraordinary” defense tactics warranted allowing an Alabama boy’s family to find a new expert witness during the case.

Judge Ramy Djerassi in the Philadelphia County Court of Common Pleas said Thursday that Janssen Pharmaceuticals Inc., which is currently appealing a $2.5 million verdict it was slapped with in the case, had waited until the last minute to raise questions about whether Missouri-based physician David Goldstein may have violated...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!